Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Stegmaier

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Leukemia|March 6, 2009
Genomic approaches to small molecule discoveryK Stegmaier
British Journal of Cancer|December 15, 2011
Genetic and proteomic approaches to identify cancer drug targetsG Roti, K Stegmaier
Current Topics in Microbiology and Immunology|January 1, 1996
Involvement of the TEL gene in hematologic malignancy by diverse molecular genetic mechanismsT R Golub, G F Barker, K Stegmaier, et al.
Current Topics in Microbiology and Immunology|January 1, 1997
The TEL gene contributes to the pathogenesis of myeloid and lymphoid leukemias by diverse molecular genetic mechanismsT R Golub, G F Barker, K Stegmaier, et al.
Biochimica Et Biophysica Acta|August 8, 1996
The TEL gene and human leukemiaT R Golub, T McLean, K Stegmaier, et al.
Cancer Research|March 15, 1996
Mutational analysis of the candidate tumor suppressor genes TEL and KIP1 in childhood acute lymphoblastic leukemiaK Stegmaier, S Takeuchi, T R Golub, et al.
Leukemia|March 29, 2013
SYK regulates mTOR signaling in AMLJ Carnevale, L Ross, A Puissant, et al.
Blood|July 1, 1995
Frequent loss of heterozygosity at the TEL gene locus in acute lymphoblastic leukemia of childhoodK Stegmaier, S Pendse, G F Barker, et al.
Blood|December 1, 1996
TEL/AML-1 dimerizes and is associated with a favorable outcome in childhood acute lymphoblastic leukemiaT W McLean, S Ringold, D Neuberg, et al.
Oncogene|March 22, 2016
Aberrant activation of the PI3K/mTOR pathway promotes resistance to sorafenib in AMLO Lindblad, E Cordero, A Puissant, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Leukemia|March 6, 2009
Genomic approaches to small molecule discoveryK Stegmaier
British Journal of Cancer|December 15, 2011
Genetic and proteomic approaches to identify cancer drug targetsG Roti, K Stegmaier
Current Topics in Microbiology and Immunology|January 1, 1996
Involvement of the TEL gene in hematologic malignancy by diverse molecular genetic mechanismsT R Golub, G F Barker, K Stegmaier, et al.
Current Topics in Microbiology and Immunology|January 1, 1997
The TEL gene contributes to the pathogenesis of myeloid and lymphoid leukemias by diverse molecular genetic mechanismsT R Golub, G F Barker, K Stegmaier, et al.
Biochimica Et Biophysica Acta|August 8, 1996
The TEL gene and human leukemiaT R Golub, T McLean, K Stegmaier, et al.
Cancer Research|March 15, 1996
Mutational analysis of the candidate tumor suppressor genes TEL and KIP1 in childhood acute lymphoblastic leukemiaK Stegmaier, S Takeuchi, T R Golub, et al.
Leukemia|March 29, 2013
SYK regulates mTOR signaling in AMLJ Carnevale, L Ross, A Puissant, et al.
Blood|July 1, 1995
Frequent loss of heterozygosity at the TEL gene locus in acute lymphoblastic leukemia of childhoodK Stegmaier, S Pendse, G F Barker, et al.
Blood|December 1, 1996
TEL/AML-1 dimerizes and is associated with a favorable outcome in childhood acute lymphoblastic leukemiaT W McLean, S Ringold, D Neuberg, et al.
Oncogene|March 22, 2016
Aberrant activation of the PI3K/mTOR pathway promotes resistance to sorafenib in AMLO Lindblad, E Cordero, A Puissant, et al.
Pageof 2